Valuation: Kadimastem

Market Cap 50.34M 5.03B 16.49M 14.65M 13.66M 12.43M 23.46M 1.59B 23.71M 166M 64.17M 810M 61.89M 60.55M 2.6B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 50.34M 5.03B 16.49M 14.65M 13.66M 12.43M 23.46M 1.59B 23.71M 166M 64.17M 810M 61.89M 60.55M 2.6B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
32.43%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-8.93% - - 16.81M
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-2.32%+23.28%+77.03% 59.26B
+0.89%-0.77%+5.80%+32.89% 47.14B
-0.96%-6.11%+26.70%+31.24% 42.91B
+0.36%+3.39%+350.59%+646.53% 44.13B
-0.20%-0.53%+6.84%+99.07% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+2.33%-8.58%-24.55%+340.08% 23.71B
Average +0.02%-0.64%+53.40%+154.55% 43.6B
Weighted average by Cap. +0.24%-0.40%+58.36%+145.81%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Kadimastem
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
Employees
11